They claim biofilm causes BII because 39% of women with BII have a biofilm — but they don't tell you that women without BII have biofilms at the same rate. If the cause is equally common in healthy people, it isn't the cause. That isn't science. That's marketing.
I've had this paper sent to me about a hundred times in the last week. It was published in ASJ (the Aesthetic Surgery Journal) and it's being used by explant influencers and breast implant illness (BII) "experts" to make claims that aren't actually supported by the evidence the paper itself analyzes.
This is a great example of why you really have to understand a subject matter before you can interpret research — and why even some papers that make it into peer-reviewed journals don't actually hold up under scrutiny.
I want to walk through the specific issues, because the conclusions of this paper are now being used to convince patients of things that aren't true and to drive them toward more invasive surgeries they don't need.
The paper is a meta-analysis — meaning the authors looked at the existing literature on a topic and pooled the results. They ended up analyzing 33 papers, of which only 7 were prospective studies.
That alone is a problem. Prospective studies (where you set up the design before you collect data) are much higher quality than retrospective studies (where you go back and analyze data after the fact). When the majority of your "evidence" is retrospective, your conclusions are inherently shaky.
So before we even get to the specific claims, the quality of the underlying evidence is poor. A meta-analysis can't produce strong conclusions from weak underlying studies — it just averages the weakness.
The paper claims that biofilm is causally linked to breast implant illness, citing that 39% of women with BII have a biofilm on their implant.
Here's what they didn't mention:
If 39% of women with BII have biofilm and 39% of women without BII also have biofilm, biofilm cannot be the cause of BII. That's basic epidemiology — to establish causation, the rate of the proposed cause has to be higher in the affected group than the unaffected group.
There's also a much more practical test: if biofilm caused BII, then patients who get their implants removed should only feel better if they had biofilm. They don't. In the data we have, patients who feel better after explant improve at the same rates whether or not they had biofilm. This finding has been repeated in the literature.
So there is no evidence biofilm is a causative agent for BII. Asserting that it is — and using that assertion to sell aggressive surgical interventions — isn't science. It's marketing.
The paper also claims an autoimmune mechanism is responsible for BII. Their evidence:
The paper cites ANA (antinuclear antibody) levels being elevated in BII patients.
Problem: ANA is elevated in approximately the same rate in the general population as it is in BII patients. Mild ANA elevations are common, non-specific, and seen in many people with no autoimmune symptoms at all.
If your "evidence" of autoimmunity is something that's present at the same rate in healthy people, that's not evidence of autoimmunity.
The paper also cites one of the ACERB trials where several interleukins were elevated in the BII cohort.
Problem: The ACERB trial cohort had significant confounders in the BII group — meaning other variables that could independently account for the interleukin elevations. The original trial authors acknowledged this. The meta-analysis didn't.
You can't take a finding from a trial with confounders, strip out the discussion of those confounders, and present it as clean evidence of autoimmunity. That's misrepresenting the source paper.
The paper mentions synovial metaplasia — a marker of inflammation in the capsule — as supporting the BII inflammatory hypothesis.
In the ACERB trial, synovial metaplasia was actually more common in the non-BII patients with implants than in the BII patients.
That's the opposite of what the meta-analysis is implying. If your "marker of BII inflammation" is more common in the people without BII, it isn't a marker of BII.
The paper makes some assertions about silicone implants specifically being the cause of BII, citing that 70% of patients in the analyzed studies had silicone implants.
Finding "more silicone implants in BII patients" when there are more silicone implants in everyone is just describing the population, not finding a cause.
Here's the cleanest argument against silicone being the cause: saline implant patients also develop BII.
If silicone exposure were the cause, BII shouldn't occur in saline implant patients, because:
But women with saline implants do report BII symptoms at meaningful rates. If silicone is the cause, this shouldn't happen. It does. So silicone isn't the cause.
Despite all of these issues, one of the videos I was sent was from an explant influencer presenting this paper as published in a top journal and saying we should all listen to it.
What that influencer didn't mention:
You can't have it both ways. You can't cite the journal as authoritative for the paper that suits your business model and ignore the paper from the same journal that contradicts it.
I want to be honest about something: even I read this paper and felt confused. The claims sound authoritative, the citations look impressive, and the conclusions read as scientific.
But when I dug into the source studies and talked to Pat McGuire — one of the authors on the ACERB trials — she had really specific, well-articulated critiques of how the meta-analysis misrepresented the underlying data.
That's how good science works: you can't just read the abstract and the conclusions. You have to read the underlying studies, understand the methodology, and check whether the conclusions are actually supported by the data.
This is also why you can't do your own research in this domain by reading PubMed abstracts. The training to interpret medical research is real, and even with that training, you sometimes need a domain expert to point out the specific things that got past peer review.
This paper is now being used to:
Meanwhile, patients with real symptoms are being told things about their bodies that aren't supported by evidence — and they're being steered toward more invasive surgeries than they need.
If you have symptoms you believe are related to your implants:
You deserve honest information and appropriately-scaled surgery, not fear-mongering used to drive aggressive operations.
This isn't just one bad paper. It's part of a recurring pattern where certain explant practitioners and BII influencers use selectively interpreted research to:
And every time I push back, I get accused of "denying patient experiences" or "protecting Big Implant." That's not what's happening. I treat BII patients regularly. I remove implants regularly. What I won't do is recommend operations that don't have evidence behind them based on a meta-analysis that misrepresents its own data.
A recent meta-analysis published in ASJ is being widely promoted as confirming that biofilm and silicone cause breast implant illness via an autoimmune mechanism. When you actually examine the paper, the conclusions are not supported by the data it analyzed:
This is a poorly done study being used to scare patients into more invasive surgeries than they need. Patients with real symptoms deserve real science — not a marketing campaign dressed up in a peer-reviewed journal.
Thank you, Pat McGuire, as always, for your phenomenal insight on this.